CA
NZ
UK
AU
IND
US
Gilead Sciences (NASDAQ:GILD) shares closed up 3.14% at $135.27, with a day range of $129.54 to $135.50 on volume of 9.50 million shares, despite the company reporting a substantial GAAP net loss for the second quarter. Investors appeared to focus on the fact that …
Novo Nordisk (NYSE:NVO) shares fell more than 6% Tuesday despite the company raising its full-year 2026 guidance, with adjusted sales now expected to range from down 6% to flat at constant exchange rates, an improvement from the prior guidance range of down 4% to …
Moderna (NASDAQ:MRNA) announced that the first participants have been vaccinated in a Phase 1 clinical trial evaluating mRNA-1469, its investigational mRNA vaccine designed to prevent disease caused by Bundibugyo ebolavirus, following authorization from Health Canada. The vaccine candidate uses the same mRNA platform technology …
Silexion Therapeutics has appointed Avner Lushi to its audit committee, effectively filling the vacancy left by Professor Peled's resignation, which took effect on August 1, 2026. Professor Peled stepped down for personal reasons, clarifying that the decision was not due to any disagreements over …
Stoke Therapeutics posted Q2 earnings per share of $‑0.79, topping the $‑0.84 consensus, while its stock slipped 1.2% to $29.21. The beat narrows valuation concerns, but the modest price decline reflects lingering skepticism over upcoming Phase 3 data and timing of the FDA meeting.Key …
The recent accident involving a teenager crashing into another driver underscores critical questions around Medicare’s liability for covering hospital bills. The injured party reported that their car was nearly 20 years old and only had liability and uninsured motorist insurance, excluding collision coverage. This …
Teladoc Health (NYSE: TDOC) announced a board expansion that lifts its director count to ten, appointing veteran executive Mark V. Anquillare as a new member. Anquillare will join both the audit and compensation committees, positioning the company for stronger oversight.
Teleflex Inc (NYSE: TFX) has successfully divested its Original Equipment Manufacturing (OEM) business for $1.5 billion, a strategic decision expected to enhance the company's financial flexibility and shareholder returns. The transaction positions Teleflex to prioritize its core operations while utilizing approximately $1.25 billion of …
Mixed earnings reports from major biotech companies have resulted in diverging outcomes for investors. Increased operating expenses were the heart of the issue, leading analysts to express surprise at the scale of the miss. On the other hand, Twist Bioscience also faced challenges, generating …
UFP Technologies Inc's net income rose 21.4% to $20.9 million in Q2, driven by 15.1% sales growth, which may support the stock's 19.8% year-to-date gain.Key HighlightsTop five customers grew 14.7%MedTech business grew 19.7%Operating income grew 15.5% to $28.1 millionThe company's strong execution and growth …
Please wait processing your request...